No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
AU Stock MarketDetailed Quotes
VBLD Vanguard Global Infrastructure ETF
- 63.000
- +1.230+1.99%
20min DelayMarket Closed Jul 12 16:00 AET
63.080High62.710Low
63.080High62.710Low7.01KVolume62.710Open61.770Pre Close442.03KTurnover66.55452wk High0.13%Turnover Ratio5.51MShares55.63352wk Low--EPS TTM347.37MFloat Cap66.554Historical High--P/E (Static)5.51MShs Float41.952Historical Low--EPS LYR0.60%Amplitude1.77Dividend TTM--P/B1Lot Size2.81%Div YieldTTM
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
NRG, ATO, SO Among Top Utilities Quant Picks Ahead of Q2 Earnings
Dividend Roundup: Procter & Gamble, Costco, CVS Health, Colgate-Palmolive, and More
Price Over Earnings Overview: Union Pacific
In the current session, the stock is trading at $228.51, after a 1.83% spike. Over the past month, Union Pacific Inc. (NYSE:UNP) stock increased by 2.88%, and in the past year, by 8.31%. With
Duke Energy Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 5.83% BMO Capital $110 → $109 Maintains Outperform 06/24/2024 -4.85% Morgan Stanley $103 → $98
Distressed Investors See 'Exceptional Bargains' In Troubled US Commercial Real Estate Sector
Distressed investors are viewing the U.S. commercial real estate industry as a utopia of great deals after the COVID-19 pandemic work-from-home shift caused office values to plummet last year.
CSX Declares $0.12 Dividend
Comments
The trial of VB-601 may add value but hiring an advisor for strategic options and reporting losses indicate resource pressure and strategy shift, thus casting doubt on future performance.
Press Release: VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateMatthew Trudeau's appointment as CCO massively benefits VBL, given his extensive experience in leading commercial practices at different biotech firms. His expertise is expected to be crucial in preparing for the anticipated OVAL Phase 3 trial readout in the second half of 2022.
EIC Accelerator funds VBL as it approaches the final enrollment phase of its key product candidate, ofra-vec (VB-111), for ovarian cancer. The CEO perceives this investment as acknowledgment of the potential ofra-vec offers to patients and the current critical need in ovarian cancer therapies.
Read more